@article{TCR10753,
author = {Jessica Felton and Jean-Pierre Raufman},
title = {Is the ColDx assay a valid prognostic marker for stage II colon cancer?},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 6},
year = {2016},
keywords = {},
abstract = {In the United States, colorectal cancer is the fourth most prevalent neoplasm and the second most frequent cause of cancer-related death (1). Surgery alone is standard-of-care for stage I cancer, whereas adjuvant chemotherapy is recommended for stage III. Surprisingly, despite its prevalence, the most appropriate management for stage II colon cancer remains uncertain. Currently-accepted guidelines recommend adjuvant chemotherapy for those considered ‘high-risk’ for recurrence, defined as stage T4 cancer, poorly-differentiated histology, inadequate lymph node sampling, positive or unknown margins, lympho-vascular or perineural invasion, bowel obstruction, or perforation (2).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/10753}
}